Dominari (DOMH)
Market Price (4/23/2026): $3.01 | Market Cap: $48.3 MilSector: Financials | Industry: Diversified Capital Markets
Dominari (DOMH)
Market Price (4/23/2026): $3.01Market Cap: $48.3 MilSector: FinancialsIndustry: Diversified Capital Markets
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -161% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 487% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -48% Attractive yieldDividend Yield is 25%, FCF Yield is 47% | Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -72% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -56 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -45% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 45% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -161% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 487% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -48% |
| Attractive yieldDividend Yield is 25%, FCF Yield is 47% |
| Weak multi-year price returns2Y Excs Rtn is -15%, 3Y Excs Rtn is -72% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -56 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -45% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 45% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26% |
Qualitative Assessment
AI Analysis | Feedback
Dominari (DOMH) stock has lost about 35% since 12/31/2025 because of the following key factors:
1. GAAP Net Loss Despite Revenue Surge: Dominari reported a GAAP net loss of $22.4 million for the full year 2025, an increase from a $14.7 million loss in 2024. This expanded loss was largely driven by $55.0 million in non-cash stock-based compensation expenses recorded in 2025, overshadowing a substantial 487% increase in preliminary revenue to $123.1 million for the same period. This divergence between strong top-line growth and a worsening GAAP net loss likely raised investor concerns regarding underlying profitability and cost management.
2. Congressional Inquiry into Chinese IPO Underwriting: On March 8, 2026, Dominari disclosed receiving a letter from the U.S. House Select Committee requesting information regarding its underwriting of Chinese company Initial Public Offerings (IPOs). While the company stated it would cooperate and clarified that Chinese IPO activity concluded in 2024 and represented less than 10% of its investment banking revenue, this inquiry introduced regulatory uncertainty that could have negatively impacted investor sentiment.
Show more
1. GAAP Net Loss Despite Revenue Surge: Dominari reported a GAAP net loss of $22.4 million for the full year 2025, an increase from a $14.7 million loss in 2024. This expanded loss was largely driven by $55.0 million in non-cash stock-based compensation expenses recorded in 2025, overshadowing a substantial 487% increase in preliminary revenue to $123.1 million for the same period. This divergence between strong top-line growth and a worsening GAAP net loss likely raised investor concerns regarding underlying profitability and cost management.
2. Congressional Inquiry into Chinese IPO Underwriting: On March 8, 2026, Dominari disclosed receiving a letter from the U.S. House Select Committee requesting information regarding its underwriting of Chinese company Initial Public Offerings (IPOs). While the company stated it would cooperate and clarified that Chinese IPO activity concluded in 2024 and represented less than 10% of its investment banking revenue, this inquiry introduced regulatory uncertainty that could have negatively impacted investor sentiment.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -33.5% change in DOMH stock from 12/31/2025 to 4/22/2026 was primarily driven by a -42.5% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.51 | 3.00 | -33.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 102 | 123 | 20.2% |
| P/S Multiple | 0.7 | 0.4 | -42.5% |
| Shares Outstanding (Mil) | 15 | 16 | -3.7% |
| Cumulative Contribution | -33.5% |
Market Drivers
12/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| DOMH | -33.5% | |
| Market (SPY) | -5.4% | 45.6% |
| Sector (XLF) | -4.7% | 46.2% |
Fundamental Drivers
The -53.6% change in DOMH stock from 9/30/2025 to 4/22/2026 was primarily driven by a -77.3% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.46 | 3.00 | -53.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 56 | 123 | 121.3% |
| P/S Multiple | 1.7 | 0.4 | -77.3% |
| Shares Outstanding (Mil) | 15 | 16 | -7.5% |
| Cumulative Contribution | -53.6% |
Market Drivers
9/30/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| DOMH | -53.6% | |
| Market (SPY) | -2.9% | 49.6% |
| Sector (XLF) | -2.7% | 45.1% |
Fundamental Drivers
The -14.6% change in DOMH stock from 3/31/2025 to 4/22/2026 was primarily driven by a -77.9% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.51 | 3.00 | -14.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13 | 123 | 877.9% |
| P/S Multiple | 1.8 | 0.4 | -77.9% |
| Shares Outstanding (Mil) | 6 | 16 | -60.5% |
| Cumulative Contribution | -14.6% |
Market Drivers
3/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| DOMH | -14.6% | |
| Market (SPY) | 16.3% | 36.2% |
| Sector (XLF) | 5.9% | 35.7% |
Fundamental Drivers
The 10.4% change in DOMH stock from 3/31/2023 to 4/22/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.72 | 3.00 | 10.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 123 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 0.4 | |
| Shares Outstanding (Mil) | 5 | 16 | -65.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/22/2026| Return | Correlation | |
|---|---|---|
| DOMH | 10.4% | |
| Market (SPY) | 63.3% | 22.4% |
| Sector (XLF) | 69.6% | 18.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DOMH Return | -33% | -67% | -21% | -62% | 443% | -38% | -78% |
| Peers Return | 41% | -13% | 8% | 56% | -21% | -13% | 44% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 88% |
Monthly Win Rates [3] | |||||||
| DOMH Win Rate | 25% | 33% | 58% | 17% | 58% | 25% | |
| Peers Win Rate | 58% | 35% | 52% | 56% | 44% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DOMH Max Drawdown | -34% | -69% | -44% | -65% | 0% | -39% | |
| Peers Max Drawdown | -9% | -29% | -37% | -29% | -39% | -31% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: FSP, BTGO, TW, LPLA, CD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/22/2026 (YTD)
How Low Can It Go
| Event | DOMH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -95.4% | -25.4% |
| % Gain to Breakeven | 2059.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -84.8% | -33.9% |
| % Gain to Breakeven | 558.6% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -93.0% | -19.8% |
| % Gain to Breakeven | 1320.4% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -93.0% | -56.8% |
| % Gain to Breakeven | 1320.0% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to FSP, BTGO, TW, LPLA, CD
In The Past
Dominari's stock fell -95.4% during the 2022 Inflation Shock from a high on 2/12/2021. A -95.4% loss requires a 2059.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Dominari (DOMH)
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
AI Analysis | Feedback
- An early-stage Amgen or Gilead Sciences, but focused on developing new small-molecule drugs for cancers and viruses.
- A research-driven Moderna or BioNTech, but for small-molecule cancer and antiviral treatments instead of vaccines.
AI Analysis | Feedback
- DHA-dFdC: A drug candidate currently in development for the treatment of pancreatic cancer.
- KPC34: A small molecule treatment under development for acute myeloid leukemia and acute lymphoblastic leukemia.
- Antiviral platform: A developing technology designed to inhibit the replication of various viruses, including influenza, Ebolavirus, and coronaviruses.
AI Analysis | Feedback
Based on the provided information, AIkido Pharma Inc. (trading under the symbol DOMH), is a biotechnology company focused on developing small-molecule anti-cancer therapeutics and an antiviral platform. The company is primarily engaged in research and development and has license agreements for its intellectual property. Therefore, its major "customers" or partners are the entities with whom it has these agreements, rather than selling approved products directly to individuals or a broad market.
The company sells primarily to other companies and institutions through licensing agreements. Its major customers/partners include:
- Silo Pharma Inc. (Symbol: SILO)
- University of Texas
- University of Maryland Baltimore
- Wake Forest University Health Sciences
AI Analysis | Feedback
nullAI Analysis | Feedback
Anthony C. Hayes, Esq., Chief Executive Officer and Chairman of the Board
Anthony C. Hayes is the driving force behind Dominari Holdings Inc.'s expansion plans, overseeing the transformation of AIkido from a biotechnology company to a diversified corporate enterprise. He is an attorney, a former partner at an Am Law 100 firm, and co-founded and was the managing member of JaNSOME IP Management LLC, an intellectual property monetization consulting firm. Hayes received special recognition from President George W. Bush for creating the 'Wills For Heroes' program. He has also been involved in multimillion-dollar M&A acquisitions.
Tim Ledwick, Chief Financial Officer
Tim Ledwick brings more than two decades of public and private company CFO experience to Dominari. He was appointed as CFO effective October 1, 2025, and previously served as the Audit Committee Chair of Dominari from 2015-2025. Most recently, he provided CFO consulting services to a Nasdaq-listed public safety technology and services company (Nasdaq: WRAP). From 2011 until 2022, he was the Chief Financial Officer of SYFT, a private equity-backed company that was successfully sold to GHX in 2022. He has also held CFO positions at Dictaphone Corporation, Lernout & Hauspie Speech Products, Cross Media Marketing Corp, and Cityscape Financial Corp.
Kyle M. Wool, President
Kyle M. Wool serves as President to the Dominari Holdings Inc. Board of Directors and is the CEO of Dominari Financial Inc. and Dominari Securities. He has over 20 years of experience in global finance, including roles as a Managing Director at Oppenheimer & Co., Head of Wealth Management for their Asian branch, Executive Director at Morgan Stanley, and President of Revere Securities LLC.
Chris Devall, Chief Operating Officer
Chris Devall brings two decades of experience and expertise in various industries, including government procurement, manufacturing, and biotech, to his role as Chief Operating Officer.
Soo Yu, Special Projects Manager
Soo Yu serves as the Special Projects Manager for Dominari Holdings Inc.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Dominari Holdings Inc. (symbol: DOMH) maintains legacy investments in biotechnology through its Aikido Labs segment, despite primarily operating as a financial services firm. The addressable markets for its main biotechnology products, focusing on cancer therapeutics and an antiviral platform, are detailed below:
- Prostate Cancer Therapeutics: The global market size for prostate cancer therapeutics was estimated at approximately USD 17.0 billion in 2024 and is projected to reach about USD 31.99 billion by 2030. Other estimates place the market at USD 25.12 billion in 2025, with a projection to reach USD 106.86 billion by 2034.
- Pancreatic Cancer Therapeutics: The global pancreatic cancer treatment market was valued at around USD 2.92 billion in 2024 and is projected to reach approximately USD 5.84 billion by 2030. Another estimate indicates a market size of US$ 4.3 billion in 2026, with a projected growth to US$ 12.6 billion by 2033.
- Acute Myeloid Leukemia (AML) Therapeutics: The global acute myeloid leukemia treatment market was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. Another report estimates the market at USD 4.28 billion in 2026, with a projection to reach approximately USD 10.64 billion by 2035.
- Acute Lymphoblastic Leukemia (ALL) Therapeutics: The global acute lymphoblastic leukemia therapeutics market size was valued at USD 3.12 billion in 2023 and is projected to grow to USD 4.99 billion by 2030. Other analyses indicate the market was valued at USD 4.04 billion in 2026, expected to reach USD 5.53 billion by 2031.
- Antiviral Platform (including influenza, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2): The global antiviral drugs market was estimated at USD 60.6 billion in 2024 and is expected to grow to USD 85.4 billion in 2034. Another source estimates the market at USD 65.13 billion in 2026, with a projection to approximately USD 89.86 billion by 2035.
AI Analysis | Feedback
Dominari Holdings Inc. (symbol: DOMH), formerly known as AIkido Pharma Inc., has undergone a significant strategic transformation, shifting its primary business focus from biotechnology to financial services. This pivot began in the second half of 2022, and the company is actively winding down its legacy biotechnology assets. Consequently, the expected drivers of future revenue growth for Dominari over the next 2-3 years are rooted in its expanding financial services operations. Here are 3-5 expected drivers of future revenue growth for Dominari (DOMH):- Expansion of Financial Services Operations: Dominari Holdings Inc., primarily through its subsidiary Dominari Financial Inc., is strategically focused on wealth management, investment banking, sales and trading, and asset management. The company has explicitly stated its long-range goal to diversify into the financial services sector, actively recruiting new team members and building out operations to support this objective. This expansion of its core financial services activities is a key driver.
- Strategic Acquisitions in the Financial Services Industry: A core component of Dominari's growth strategy involves making strategic acquisitions within the financial services sector. For instance, Dominari Financial acquired a registered broker-dealer, Fieldpoint Private Securities, LLC, which was subsequently renamed Dominari Securities LLC, to bolster its financial services offerings. Continued strategic acquisitions are expected to expand its market reach and diversify its service portfolio.
- Launch and Growth of New Financial Products and Services: Dominari is actively developing and introducing new offerings within its financial services segment. An example is the joint venture between Dominari Financial and Heritage Strategies LLC, formed in May 2024, to offer various insurance products and services. These include life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services, which are anticipated to contribute to future revenue growth.
- Increased Capital Markets Activity and Underwriting: Dominari Securities is engaged in capital markets activities and underwriting. Its approval as a Limited Underwriting Member of NYSE in September 2025 further strengthens its position in this area. Reports indicate significant growth in this segment, with Dominari Securities raising over $1.4 billion year-to-date through capital markets activity and experiencing a 520% surge in Q2 2025 revenue for this area. This continued momentum in capital markets and underwriting is expected to be a substantial revenue driver.
AI Analysis | Feedback
Share Repurchases
- In January 2022, the board authorized a share repurchase program of up to $3 million.
- During 2022, the company repurchased approximately $3.1 million in shares, including 468,017 shares.
- In December 2022, a new $2 million share repurchase program was authorized, under which the company made purchases in late 2022 and early 2023.
Share Issuance
- In February 2022, the company agreed to issue and sell 11,000 shares of Series O Redeemable Convertible Preferred Stock in a registered direct offering.
- In August 2025, Dominari Holdings filed a shelf registration statement enabling the potential future offer and sale of up to $2 billion worth of common stock, preferred stock, or a combination thereof.
- In March 2026, stockholders approved increasing the shares reserved for issuance under the 2022 Equity Incentive Plan by 10 million shares, raising the total pool from 11,720,750 to 21,720,750 shares, with an additional automatic annual increase feature from 2027 to 2032.
Inbound Investments
- The company raised approximately $13.5 million subsequent to December 31, 2024, to fund its operations.
- As of September 30, 2025, Dominari held significant cash and marketable securities totaling $176.2 million, resulting in the withdrawal of a $2 billion shelf registration statement as additional capital was not required at that time.
Outbound Investments
- In January 2021, the company invested in Convergent Therapeutics, Inc., a firm focused on next-generation prostate cancer therapy. Subsequently, during 2021, the company also made investments in DatChat, Inc. (which resulted in a 600% return on investment), Tevva Motors, and Kerna Health ($1.0 million for 1,333,334 shares).
- In 2023, as part of its strategic shift to financial services, Dominari Financial completed the acquisition of Fieldpoint Private Securities, LLC, a broker-dealer and investment advisor.
- In 2024, Dominari Financial entered into a joint venture with Heritage Strategies LLC to establish Dominari Financial Heritage Strategies LLC, focusing on offering various insurance products and services.
Capital Expenditures
- Approximately $3.2 million of capital was deployed in 2022 to establish and operate its financial services subsidiary, Dominari Financial Inc., which included the acquisition of a broker-dealer.
- Dominari plans to continue expanding its financial services operations and seeks additional capital to support future growth and operational needs.
- The company aims to enhance stockholder value by pursuing opportunities outside its current business, including in the AI and Data Center sectors, while also providing management support to its subsidiaries for efficient and cost-effective operations.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Dominari Earnings Notes | 12/16/2025 | |
| null | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to DOMH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | HBAN | Huntington Bancshares | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 03312026 | NP | Neptune Insurance | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 03272026 | JKHY | Jack Henry & Associates | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 3.1% | 3.1% | 0.0% |
| 03202026 | MKTX | MarketAxess | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -5.2% | -5.2% | -5.7% |
| 03202026 | RYAN | Ryan Specialty | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | -2.7% | -2.7% | -8.5% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.66 |
| Mkt Cap | 24.3 |
| Rev LTM | 1,088 |
| Op Inc LTM | 2 |
| FCF LTM | 19 |
| FCF 3Y Avg | -10 |
| CFO LTM | 23 |
| CFO 3Y Avg | 68 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 18.9% |
| Rev Chg 3Y Avg | 3.3% |
| Rev Chg Q | 40.4% |
| QoQ Delta Rev Chg LTM | 9.1% |
| Op Inc Chg LTM | -28.9% |
| Op Inc Chg 3Y Avg | -177.4% |
| Op Mgn LTM | -3.7% |
| Op Mgn 3Y Avg | 4.2% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | 3.5% |
| CFO/Rev 3Y Avg | 4.7% |
| FCF/Rev LTM | 0.1% |
| FCF/Rev 3Y Avg | -7.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 24.3 |
| P/S | 1.5 |
| P/Op Inc | -0.9 |
| P/EBIT | -0.9 |
| P/E | -1.5 |
| P/CFO | 9.9 |
| Total Yield | -0.1% |
| Dividend Yield | 0.4% |
| FCF Yield 3Y Avg | -5.1% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.4% |
| 3M Rtn | -19.2% |
| 6M Rtn | -38.6% |
| 12M Rtn | -17.8% |
| 3Y Rtn | 28.1% |
| 1M Excs Rtn | -3.0% |
| 3M Excs Rtn | -23.0% |
| 6M Excs Rtn | -46.4% |
| 12M Excs Rtn | -52.2% |
| 3Y Excs Rtn | -41.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dominari Financial | 2 | ||||
| Legacy AIkido Pharma | 0 | ||||
| Single segment | 0 | ||||
| Total | 2 | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Legacy AIkido Pharma | -9 | ||||
| Dominari Financial | -12 | ||||
| Total | -22 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Legacy AIkido Pharma | -11 | ||||
| Dominari Financial | -12 | ||||
| Total | -23 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Legacy AIkido Pharma | 49 | ||||
| Dominari Financial | 9 | ||||
| Single segment | 76 | 103 | 30 | ||
| Total | 58 | 76 | 103 | 30 |
Price Behavior
Price Behavior
| Market Price | $3.00 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -55.6% | |
| 50 Days | 200 Days | |
| DMA Price | $3.08 | $4.37 |
| DMA Trend | down | down |
| Distance from DMA | -2.7% | -31.3% |
| 3M | 1YR | |
| Volatility | 70.9% | 89.5% |
| Downside Capture | 1.49 | 1.50 |
| Upside Capture | 280.65 | 201.30 |
| Correlation (SPY) | 44.5% | 40.0% |
DOMH Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.59 | 3.00 | 2.12 | 2.95 | 1.67 | 1.76 |
| Up Beta | 0.90 | 3.50 | 2.67 | 3.38 | 1.43 | 1.70 |
| Down Beta | 2.47 | 2.21 | 2.66 | 3.91 | 1.47 | 1.54 |
| Up Capture | 447% | 331% | 122% | 152% | 268% | 622% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 18 | 29 | 55 | 121 | 348 |
| Down Capture | 150% | 272% | 191% | 223% | 157% | 112% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 22 | 31 | 68 | 127 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DOMH | |
|---|---|---|---|---|
| DOMH | -16.1% | 89.6% | 0.19 | - |
| Sector ETF (XLF) | 15.6% | 15.1% | 0.76 | 37.8% |
| Equity (SPY) | 26.7% | 12.5% | 1.77 | 41.3% |
| Gold (GLD) | 38.9% | 27.4% | 1.19 | 8.6% |
| Commodities (DBC) | 23.5% | 16.2% | 1.32 | 8.1% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | 26.4% |
| Bitcoin (BTCUSD) | -12.8% | 42.6% | -0.21 | 32.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DOMH | |
|---|---|---|---|---|
| DOMH | -24.1% | 99.5% | 0.11 | - |
| Sector ETF (XLF) | 10.0% | 18.7% | 0.42 | 17.9% |
| Equity (SPY) | 10.5% | 17.1% | 0.48 | 21.6% |
| Gold (GLD) | 21.5% | 17.8% | 0.99 | 7.6% |
| Commodities (DBC) | 10.7% | 18.8% | 0.47 | 6.8% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 15.7% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 14.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DOMH | |
|---|---|---|---|---|
| DOMH | -27.1% | 127.1% | 0.23 | - |
| Sector ETF (XLF) | 12.9% | 22.2% | 0.53 | 3.1% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 4.7% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | 1.0% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | -1.5% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 2.3% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.